Literature DB >> 33402488

The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: A SEER Population Analysis.

Dimitrios Giannis1, Sara Morsy2, Georgios Geropoulos3, Stepan M Esagian4, Georgios S Sioutas4, Dimitrios Moris5.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) subtypes differ in terms of histopathology and prognosis. Sarcomatoid HCC is rare and literature concerning the survival of patients with sarcomatoid HCC is scarce.
MATERIALS AND METHODS: Data of patients with sarcomatoid HCC, diagnosed from 1989 to 2016, were extracted from the Surveillance, Epidemiology and End Results (SEER) database. We evaluated the baseline and tumor related data, overall survival (OS), disease-specific survival and the performance (Harrell's concordance index - OS c-index) of the eighth edition of the American Joint Committee on Cancer TNM staging system (AJCC8). In addition, univariate and multivariate forward stepwise cox regression analyses were performed to identify factors associated with increased risk of death.
RESULTS: The SEER cohort consisted of 71 patients, mostly males (n=49, 69.0%), of White race (n=51, 71.8%) and the most common stage at presentation was stage IVB (n=30, 42.3%). The overall predictive ability of AJCC8 was mediocre, with an OS c-index=0.577 (SE=0.048). Surgery (hazard ratio=0.25, p<0.001) was significantly associated with reduced risk of death. Advanced TNM stage was not associated with increased risk of death.
CONCLUSION: Sarcomatoid HCC, a rare subtype of HCC, is associated with poor outcomes in terms of overall and disease-specific survival across all disease stages. Surgery seems to be of utmost importance. The eighth edition of the AJCC8 for HCC underperforms in predicting the survival of patients with sarcomatoid subtype. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  AJCC; Hepatocellular carcinoma; SEER; sarcomatoid

Mesh:

Year:  2021        PMID: 33402488      PMCID: PMC7880738          DOI: 10.21873/invivo.12270

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  43 in total

Review 1.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

2.  Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis.

Authors:  Lu Wu; Diamantis I Tsilimigras; Ayesha Farooq; J Madison Hyer; Katiuscha Merath; Anghela Z Paredes; Rittal Mehta; Kota Sahara; Feng Shen; Timothy M Pawlik
Journal:  Cancer       Date:  2019-07-12       Impact factor: 6.860

3.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

Review 4.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

5.  Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients.

Authors:  Diamantis I Tsilimigras; Fabio Bagante; Dimitrios Moris; Katiuscha Merath; Anghela Z Paredes; Kota Sahara; Francesca Ratti; Hugo P Marques; Olivier Soubrane; Vincent Lam; George A Poultsides; Irinel Popescu; Sorin Alexandrescu; Guillaume Martel; Aklile Workneh; Alfredo Guglielmi; Tom Hugh; Luca Aldrighetti; Itaru Endo; Timothy M Pawlik
Journal:  Surgery       Date:  2019-10-09       Impact factor: 3.982

Review 6.  Molecular therapies for HCC: Looking outside the box.

Authors:  Sandrine Faivre; Lorenza Rimassa; Richard S Finn
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

7.  Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era.

Authors:  Chintan Shah; Lazarus K Mramba; Rohit Bishnoi; Harini Bejjanki; Hardik Satish Chhatrala; Sreenivasa R Chandana
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 8.  From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.

Authors:  Dimitrios Dimitroulis; Christos Damaskos; Serena Valsami; Spyridon Davakis; Nikolaos Garmpis; Eleftherios Spartalis; Antonios Athanasiou; Demetrios Moris; Stratigoula Sakellariou; Stylianos Kykalos; Gerasimos Tsourouflis; Anna Garmpi; Ioanna Delladetsima; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

Review 9.  Evolving role of Sorafenib in the management of hepatocellular carcinoma.

Authors:  Ioannis A Ziogas; Georgios Tsoulfas
Journal:  World J Clin Oncol       Date:  2017-06-10

10.  A comparison of model selection methods for prediction in the presence of multiply imputed data.

Authors:  Le Thi Phuong Thao; Ronald Geskus
Journal:  Biom J       Date:  2018-10-23       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.